Details of the Drug

General Information of Drug (ID: DM43GPX)

• Drug Name: BVI-007

Indication

Disease Entry	ICD 11	Status	REF
Myocardial infarction	BA41-BA43	Phase 1	[1]
Thrombotic stroke	8B20	Phase 1	[1]

• Cross-matching ID: TTD ID: D04KVA

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thrombopoietin (THPO)	TTCG5PE	TPO_HUMAN	Inhibitor	[2], [3]
Thrombopoietin receptor (MPL)	TTIHYA4	TPOR_HUMAN	Antagonist	[4]

Molecular Expression Atlas of This Drug

• The Studied Disease: Myocardial infarction
• ICD Disease Classification: BA41-BA43

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Thrombopoietin receptor (MPL)	DTT	MPL	8.96E-01	0.07	0.28

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027040)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
• [5] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [6] Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
• [7] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [8] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [9] A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.